These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

974 related items for PubMed ID: 17303994

  • 21. Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
    Jackson G.
    Int J Clin Pract; 2001 Apr; 55(3):183-8. PubMed ID: 11351772
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM, Turrentine MW, Sheridan BC, Wang M, Fiore AC, Brown JW, Meldrum DR.
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [Abstract] [Full Text] [Related]

  • 24. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
    Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C.
    Int J Impot Res; 1996 Jun; 8(2):47-52. PubMed ID: 8858389
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treatment of erectile dysfunction.
    Dinsmore W.
    Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF.
    Ned Tijdschr Geneeskd; 2006 Jul 22; 150(29):1613-6. PubMed ID: 16901064
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A, EDOS Group.
    Int J Clin Pract; 2007 Nov 22; 61(11):1850-62. PubMed ID: 17850306
    [Abstract] [Full Text] [Related]

  • 38. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
    Schwartz BG, Kloner RA.
    Circulation; 2010 Jul 06; 122(1):88-95. PubMed ID: 20606131
    [No Abstract] [Full Text] [Related]

  • 39. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
    Toque HA, Priviero FB, Teixeira CE, Claudino MA, Baracat JS, Fregonesi A, De Nucci G, Antunes E.
    Urology; 2009 Jul 06; 74(1):216-21. PubMed ID: 19371941
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.